Fidelity Investments
HBIO icon

Fidelity Investments’s Harvard Bioscience HBIO Stock Holding History

Fidelity Investments’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.6K Sell
3,179
-95
-3% -$569 ﹤0.01% 4672
2026
Q1 		$15.9K Sell
3,274
-16
-0.5% -$89 ﹤0.01% 4605
2025
Q4 		$22K Sell
3,290
-1,269
-28% -$7.53K ﹤0.01% 4421
2025
Q3 		$20K Sell
4,559
-2,668
-37% -$12.7K ﹤0.01% 4359
2025
Q2 		$32.1K Buy
7,227
+4,924
+214% +$20.6K ﹤0.01% 4096
2025
Q1 		$13K Buy
2,303
+1,792
+351% +$22.9K ﹤0.01% 4395
2024
Q4 		$10.8K Buy
511
+81
+19% +$1.86K ﹤0.01% 4448
2024
Q3 		$11.6K Buy
430
+5
+1% +$147 ﹤0.01% 4382
2024
Q2 		$12.1K Buy
425
+419
+6,983% +$14.7K ﹤0.01% 4262
2024
Q1 		$250 Sell
6
-21
-78% -$944 ﹤0.01% 4906
2023
Q4 		$1.42K Buy
27
+22
+440% +$993 ﹤0.01% 4707
2023
Q3 		$206 Buy
5
+1
+25% +$46 ﹤0.01% 4787
2023
Q2 		$220 Buy
+4
New +$219 ﹤0.01% 4892
2022
Q3 		– Sell
-37
Closed -$1K – 5108
2022
Q2 		$1K Sell
37
-101
-73% -$4.56K ﹤0.01% 4720
2022
Q1 		$8K Buy
138
+99
+254% +$5.86K ﹤0.01% 4293
2021
Q4 		$3K Buy
+39
New +$2.77K ﹤0.01% 3928
2016
Q2 		– Sell
-10,738
Closed -$324K – 2665
2016
Q1 		$324K Buy
10,738
+1,160
+12% +$32.9K ﹤0.01% 2587
2015
Q4 		$332K Hold
9,578
– – ﹤0.01% 2649
2015
Q3 		$362K Sell
9,578
-46,024
-83% -$2.14M ﹤0.01% 2621
2015
Q2 		$3.17M Buy
55,602
+45,914
+474% +$2.61M ﹤0.01% 2357
2015
Q1 		$564K Hold
9,688
– – ﹤0.01% 2597
2014
Q4 		$549K Buy
+9,688
New +$462K ﹤0.01% 2625
2013
Q3 		– Sell
-198,854
Closed -$7.13M – 2637
2013
Q2 		$7.13M Buy
+198,854
New +$7.61M ﹤0.01% 2032

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $118M AUM
MIM
Meros Investment Management Dallas, Texas $315M AUM 58.44% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
CCM
Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments's HBIO Position: Q2 2026 in Review

Fidelity Investments reduced its Harvard Bioscience (HBIO) stake by 2.9% in Q2 2026, selling an estimated $569 and leaving 3,179 shares worth $19.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4672.

Fidelity Investments first reported a position in HBIO in Q2 2013 and has held it in 23 quarters since. The position peaked at $7.13M in Q2 2013. 37 funds tracked by Wall St. Rank hold HBIO as of Q2 2026.

  • Fidelity Investments held 3,179 shares of Harvard Bioscience worth $19.6K as of Q2 2026.
  • Fidelity Investments sold 95 Harvard Bioscience shares in Q2 2026, an estimated $569.
  • Harvard Bioscience made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #4672 holding.
  • Fidelity Investments first reported a position in Harvard Bioscience in Q2 2013 and has held it in 23 quarters since.
  • Fidelity Investments's Harvard Bioscience position peaked at $7.13M in Q2 2013.
  • 37 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.